Routine Screening for Depression Like We Screen for HypertensionPremiere Date: Monday, March 25, 2019
This activity offers CE credit for:%>
- Physicians (CME)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, March 25, 2020
|Gregory W. Mattingly, MD
Associate Clinical Professor
Washington University School of Medicine
St. Louis, MO
President, Midwest Research Group
Midwest Research Group
St. Charles, MO
Board of Directors, APSARD - American Professional Society for ADHD and Related Disorders
Depression is a common, debilitating disorder affecting 12.8% of adolescents and 6.7% of adults in the United States. Routine depression screening is critical to ensure opportunities are not missed to provide patient treatment.
The role of primary care in screening, detection, and treatment of depression has grown, becoming the point-of-care where most people seek treatment. A recent study of five health care systems was published representing data from 241,251 adults newly diagnosed with depression in primary care settings. Efforts to improve depression outcomes in primary care have focused on improved screening, but in the study population, only 11% of patients had a PHQ-9 score measured and recorded on the index date of diagnosis, demonstrating a significant gap in the utilization of screening tools.
In part one of this free CME Outfitters Snack series, expert faculty present an engaging, focused video discussion using the ArchViewer platform to discuss improved screening and use of measurement-based care in patients with depression.
At the end of this CE activity, participants should be able to:
- Effectively screen for depression in 2 minutes or less during routine office visits.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Describe validated tools for screening individuals for depression during routine office visits.
Supported by an educational grant from Otsuka America Pharmaceutical, Inc and Lundbeck.
Primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who manage patients with depression.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Mattingly reports that he is a consultant for Alkermes; Allergan; FORUM Pharmaceuticals Inc.; Lundbeck; Merck & Co., Inc.; Otsuka America Pharmaceutical, Inc.; Purdue Pharma L.P.; Rhodes Pharmaceuticals L.P.; Shire; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Vanda Pharmaceuticals. He receives research grants from Akili Interactive Labs, Inc.; Alcobra Ltd; Alkermes; Allergan; Boehringer Ingelheim; FORUM Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Medgenics; NLS-1 Pharma AG; Reckitt Benckiser Group plc; Shire; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is on the speakers bureaus for Allergan; Alkermes; Lundbeck; Merck & Co., Inc.; NEOS Therapeutics, Inc.; Otsuka America Pharmaceutical, Inc.; Shire; Sunovio Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Vanda Pharmaceuticals.
Dr. Helfand (peer reviewer) has no disclosures to report.
Ms. Ochoa (peer reviewer) has no disclosures to report.
Kashemi D. Rorie, PHD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).